Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ripasudil,Timolol Maleate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Drugs Launches Ripasudil-Timolol Combination Therapy for Glaucoma in India
Details : Ripasudil-Timolol combination therapy is approved by the DCGI for glaucoma treatment in India and Akums becoming reportedly the first Indian CDMO to receive approval for this formulation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2025
Lead Product(s) : Ripasudil,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable